

## REVIEW ARTICLE

# Splitting p63

Hans van Bokhoven and Han G. Brunner

Department of Human Genetics, University Medical Centre Nijmegen, Nijmegen, The Netherlands

**Causative *TP63* mutations have been identified in five distinct human developmental disorders that are characterized by various degrees of limb abnormalities, ectodermal dysplasia, and facial clefts. The distribution of mutations over the various p63 protein domains and the structural and functional implications of these mutations establish a clear genotype-phenotype correlation.**

### Introduction

Different syndromes can result from mutations in a single gene. Quite often, these represent variations in severity, as do the *FGFR3* mutations, which cause hypochondroplasia, achondroplasia, and thanatophoric dysplasia. More-divergent phenotypes may reflect the difference between gain-of-function and loss-of-function mutations, as occurs with dominant brachydactyly type B and recessive Robinow syndrome, which are caused by different mutations of the *ROR2* gene. Other examples of allelic heterogeneity reflect a selective disruption of some but not all the gene's functions, as in the contrast, because of an *FGFR2* mutation, between Apert and Crouzon syndromes. For some genes there are multiple phenotypes associated with mutations, but a clear genotype-phenotype correlation is lacking. A striking example of such allelic heterogeneity are the *GLI3* morphopathies: Greig syndrome, Pallister-Hall syndrome, preaxial polydactyly type IV, and postaxial polydactyly type A/B. We here review the spectrum of p63 mutations that have been found to underlie five human malformation syndromes: ectrodactyly–ectodermal dysplasia–clefting (EEC) syndrome (MIM 604292), ankyloblepharon–ectodermal dysplasia–clefting (AEC) syndrome (MIM 106260), limb-mammary syndrome (LMS [MIM 603543]), acro-dermato-ungual-lacrimal-tooth (ADULT) syndrome (MIM 103285), and nonsyndromic split-hand/split-foot malformation (SHFM). The localization and functional effects of the mutations that underlie these syndromes establish a striking genotype-phenotype correlation. Functional analysis of these mutations has provided valuable new insights

into p63 protein structure and function and has provided a basis for further dissection of molecular and cellular pathways involving p63.

### p63 Completes the p53/p73 Family

*TP53* is the principal tumor-suppressor gene, being mutated in >50% of human cancers (Levine 1997). The p53 protein is a key regulator of the cell cycle and, to prevent damaged cells from becoming uncontrolled, allows completion of genomic-repair processes before the cell cycle proceeds. For the past 20 years, p53 has continued to surprise biomolecular researchers—publications on p53 that were listed in PubMed numbered 23,500 by January 2002. For this reason, the discovery of two genes related to *TP53*, denoted as “*TP73*” and “*TP63*,” created considerable excitement among tumor biologists (Jost et al. 1997; Kaghad et al. 1997; Schmale and Bamberger 1997; Osada et al. 1998; Senoo et al. 1998; Trink et al. 1998; Yang et al. 1998). It is now evident that *TP73* and *TP63* do not represent classical tumor-suppressor genes. Rather, they act as key regulators in development—p73 in the development of neuronal and pheromonal pathways (Yang et al. 2000) and p63 in limb, epithelial, and craniofacial development (Mills et al. 1999; Yang et al. 1999). Both p63 and p73 exhibit high amino acid identity with p53, especially among their transactivation (TA) domains, DNA-binding domain (DBD), and tetramerization (ISO) domain (fig. 1). Unlike *TP53*, both *TP63* and *TP73* encode a number of isoforms (fig. 1). For both *TP63* and *TP73*, two transcription initiation sites were initially described—one that would give rise to proteins containing the TA domain (the TA isotypes) and another that would give rise to proteins lacking this domain (the  $\Delta N$  isotypes). For *TP63*, additional transcripts were subsequently uncovered in human and rodents, resulting from both the use of at least four transcription initiation sites and extensive alternative splicing at the 5' end of the gene (Schmale and Bamberger 1997; Yang et al. 1998; Hagi-

Received April 1, 2002; accepted for publication April 26, 2002; electronically published May 30, 2002.

Address for correspondence and reprints: Dr. Hans van Bokhoven, Department of Human Genetics, 417 University Medical Centre, Nijmegen, Box 9101, 6500 HB Nijmegen, The Netherlands. E-mail: H.vanbokhoven@antrg.azn.nl


© 2002 by The American Society of Human Genetics. All rights reserved. 0002-9297/2002/7101-0002\$15.00

wara et al. 1999; Bamberger and Schmale 2001). Additionally, extensive alternative splicing is seen at the 3' end of the gene, resulting in three different C-termini for p63 and six for p73. For *TP63*, differential splicing of intron 8 creates additional variability in the final polypeptide sequences (either GTKRP or A), but the functional significance of this is not known. The extended 3' coding sequences of the  $\alpha$  isoforms of *TP63* and *TP73* encode a protein-protein-interaction motif that resembles the sterile- $\alpha$ -motif (SAM) domain (Schultz et al. 1997; Bork and Koonin 1998), which is not contained in p53. SAM domains are small globular protein-protein-interaction modules that are usually involved in homo- and hetero-oligomerization with other SAM domains. It has been demonstrated that the p63 and p73 SAM domains do not oligomerize with one another (Chi et al. 1999), and the interacting proteins still need to be identified. Besides these major structural protein motifs, all members of the p53 family contain, in front of the DBD, proline-rich domains, which are involved in pro-apoptotic activity and in the capacity to activate target sequences (Zhu et al. 1999). A second proline-rich region is located between the ISO and SAM domains in p63 and p73 but not in p53. This proline-rich domain is engaged in a physical association with

the YES-associated protein YAP. The binding of YAP to p73 $\alpha$  enhances its transcriptional activity at known p73-responsive elements (Strano et al. 2001).

### Differential Properties of the p63 Isoforms

From the primary sequence, one would predict that only the p63 isoforms, which contain the acidic TA domain, have transactivation activity, whereas the  $\Delta N$  isoforms, which lack this domain, do not have transactivation activity. Although this is generally true, there are still some exceptions to this rule. The largest p63 isoform, TA-p63 $\alpha$ , is unable to drive transcription on the optimized p53-responsive element PG13, in contrast to TA-p63 $\beta$  and TA-p63 $\gamma$  (Yang et al. 1998) (fig. 1). This unexpected lack of activity is caused by an inhibitory effect that is contained within the  $\alpha$ -specific C-terminal end. This inhibitory activity of the  $\alpha$  tail also acts in *trans* toward TA-p63 $\beta/\gamma$  transcriptional activation, indicating that the various p63 isoforms can have opposing properties. The repressive activity has been mapped to the region, downstream from the SAM domain, that has been denoted as the "transactivation inhibitory domain" (TID) (Ozaki et al. 1999; V. Doetsch, personal communication). Tentative



**Figure 1** Structure of both *TP63* and major protein isoforms. *TP63* uses several transcription initiation sites (*arrows*) and extensive alternative splicing, to generate a bewildering number of different mRNAs. For clarity, several alternative-splicing routes at the 5' end of the gene have not been indicated. Several protein domains can be distinguished; of these, the TA domains, the DBD, and the ISO domain are highly homologous to the corresponding domains in p53. The SAM domain and the TID are not contained in the p53 protein. The capacity to transactivate gene expression at a p53-responsive target is given for each of the indicated isoforms.

evidence suggests the presence of other regions within p63 that either promote or repress transactivation activity. For example, the N-terminal TA-isotype variants that contain an additional 39 amino acids (TA\*) are unable to drive transcription from the PG13 target sequence (Yang et al. 1998). Interestingly, activation of transcription can be mediated by p63 domains other than the canonical TA domain (Dohn et al. 2001; Strano et al. 2001; Duijf et al. 2002; also, see the “Genotype-Phenotype Correlations: Molecular Dissection of the p63 Gene” section, below). That all known and predicted isoforms contain the tetramerization domain creates an enormous potential for the number of possible different p63 tetrameric complexes that can be formed. Whether all possible complexes occur *in vivo* remains to be demonstrated.

### Regulation of p63 Protein Levels

Activation of the tumor suppressor p53 occurs in response to a number of stressors, including DNA damage, hypoxia, oncogene activation, and UV irradiation (Vogelstein et al. 2000). The main level of activation is mediated by posttranslational protein modifications, which affect protein function and protein stability. UV-B-induced DNA damage decreases levels of  $\Delta N$ -p63 $\alpha$  (a naturally occurring dominant-negative form of the protein), before increasing levels of p53 (Liefer et al. 2000; Yang et al. 2002). Simultaneously, the levels of the transactivating TA-p63 isoforms increase. The down-regulation of dominant-negative  $\Delta N$ -p63 $\alpha$ , as well as the up-regulation that activates TA-p63 isoforms, may be a prerequisite for UV-induced apoptosis in skin (Liefer et al. 2000). This notion is supported by the recent observation that the transactivating TA-p63 $\alpha$  (and TA-p73 $\alpha$ ) isoforms are required for p53-dependent apoptosis induced by DNA damage (Flores et al. 2002). The role that this switch from inhibitory to activating p63 isoforms plays in normal skin development is further discussed below (see “p63 in Mammalian Embryonic Development”).

Little is known about p63 protein activation and turnover. For p53, protein levels are tightly controlled by the ubiquitin ligase MDM2, which promotes the rapid degradation, by the proteasome pathway, of p53 (Haupt et al. 1997; Kubbutat et al. 1997). However, conflicting results have been reported regarding the regulation, by ubiquitination through MDM2 and the related protein MDMX, of p63. For example, in three different studies, MDM2 was shown to have either a repressive effect, a stimulatory effect, or no effect at all on p63-mediated transactivation (Kadakia et al. 2001; Little and Jochemsen 2001; Calabro et al. 2002). Very likely, these conflicting data are the result of variability in both experimental design and the type of cell lines that were used in these studies. One should be extremely

cautious in interpreting the results of these and similar studies that are characterized by directive analyses based on knowledge previously obtained for p53.

### Upstream and Downstream from p63: Smad and Jagged

A major breakthrough in our knowledge of upstream factors that control *TP63* expression was recently established in a screen for genes that are positively regulated by bone morphogenetic proteins (Bmps) during zebrafish gastrulation. A differential display strategy identified  $\Delta N$ -p63 $\alpha$  as a direct transcriptional target of Bmp signaling (Bakkers et al. 2002). The early expression of  $\Delta N$ -p63 $\alpha$  appears to be driven by Smad4 and Smad5, which are common mediators of Bmp signaling. Accordingly, Smad4 and Smad5 binding sites are present in the  $\Delta N$ -p63 promoter (Bakkers et al. 2002). Bmps promote the specification of ventral cell types in both the mesoderm and the ectoderm, along the dorsoventral axis of vertebrate embryos. In contrast, dorsal cell types, such as the dorsal mesoderm and the neuroectoderm, are formed unless they are instructed by Bmps not to do so. This is known as the “neural default” model. The zebrafish studies revealed that the effect that the Bmps have on the counteraction of this neural default occurs through  $\Delta N$ -p63 $\alpha$ , which acts as the neural repressor.

After the isolation of *TP63*, it was readily established that the corresponding p63 proteins were able to bind to an engineered p53-responsive element, PG13, and to activate transcription of a downstream reporter gene (Yang et al. 1998). Overexpression of p63 in mammalian cell lines or in yeast can activate or repress the promoters of several p53-responsive genes, including p21, Bax, MDM2, GADD45, 14-3-3 $\sigma$ , and EGFR (Osada et al. 1998; Shimada et al. 1999; Pochampally et al. 2000; Dohn et al. 2001; Nishi et al. 2001; L. Guerrini, personal communication). It is not clear, however, whether p53-responsive genes are also regulated by p63 under physiological conditions. Transfection experiments in keratinocyte cell lines revealed that TA-p63 promotes the expression of loricrin and involucrin, two markers of terminal differentiation of epidermal cells (De Laurenzi et al. 2000). Again, the physiological significance of this observation is not known, although one may speculate that p63 is involved in epidermal differentiation through loricrin and involucrin. The first and only bona fide target genes for p63 are *Jagged1* (*JAG1*) and *Jagged2* (*JAG2*), which encode ligands for Notch receptors (Sasaki et al. 2002). A cDNA microarray analysis showed an increased *JAG1* and *JAG2* expression in cell lines that were transfected with adenoviral vectors expressing TA-p63 $\gamma$ . The physiological significance of this result was convincingly demonstrated by chromatin-immunoprecipitation experiments, which revealed binding of TA-p63 $\gamma$  to promoter

elements of *JAG1* in vivo. Also, co-culturing of Notch1-expressing Jurkat cells with p63-transfected cells led to an up-regulation of *HES-1*, a downstream target of Notch signaling. This indicates that p63 can trigger the Notch pathway in neighboring cells, possibly by induction of *JAG1* and *JAG2*. Although *JAG1* mutations cause Alagille syndrome in humans, no human disease has been linked to *JAG2* mutations. Interestingly, mice with homozygous inactivating *Jag2* mutations have syndactyly and defective craniofacial development, including cleft palate (CP) (Sidow et al. 1997; Jiang et al. 1998). Much work still needs to be done to elucidate other in vivo targets of p63 transactivation and to determine the downstream effects of this transactivation.

### p63 in Mammalian Embryonic Development

The spatiotemporal expression of the individual *TP63* transcripts has not yet been explored in great detail. Immunohistochemical analyses of mouse embryos show high p63 levels in epithelial cells, especially in progenitor or stem-cell populations of epithelial tissues (Yang et al. 1998, 1999; Mills et al. 1999). The main isotype in these cells is the dominant-negative  $\Delta N$ -p63 $\alpha$  isotype, which likely acts in the maintenance of the proliferative capacity of such cells (Yang et al. 1999). As these cells start to differentiate, their  $\Delta N$ -p63 $\alpha$  levels gradually drop, and the levels of TA-p63 increase. It thus appears that dominant-negative  $\Delta N$ -p63 $\alpha$  is crucial for the maintenance of the capacity of regenerative proliferation of epithelial stem cells. Cells that no longer express  $\Delta N$ -p63 $\alpha$  lose this capacity and are committed to differentiation—and eventually reach terminal differentiation (Yang and McKeon 2002). Indeed, application of retinoic acid, which prevents degradation of  $\Delta N$ -p63 $\alpha$ , effectively blocks the differentiation of skin epithelial stem cells (i.e., keratinocytes) in culture (Bamberger et al. 2002).

In mouse embryos, *TP63* expression is first evident in nuclei of cells in the basal layer, which develop into the progenitor cells of the epidermis and related derivatives, such as hair and sweat glands. Basal cells of the cervix, tongue, esophagus, mammary glands, prostate, and urothelium also show high levels of p63. Early *TP63* expression is further evident in ectodermal cells of the limb buds and tail bud, branchial arches, and the oral epithelium. In the developing limb bud, *TP63* expression is restricted to the apical ectodermal ridge (AER), a key determinant of limb-bud emergence and progression. Proper signaling along the antero-posterior axis between the AER and the underlying mesoderm is crucial for normal formation of the distal limb. The sites of *TP63* expression are well in line with the phenotypic consequences of homozygous *TP63* inactivation in mice. These p63-deficient newborns exhibit striking limb defects. The forelimbs are severely truncated, and

the hindlimbs are lacking altogether. The skin of the knockout animals is absent, and newborn animals die from dehydration shortly after birth. Other skin derivatives, such as hair shafts and follicles are not present. Finally, p63-deficient animals lack tooth primordia and eyelids. Both the maxilla and the mandible are truncated, and the secondary palate fails to close. Taken together, the defects in p63-deficient mice present as severe ectodermal dysplasia, abnormal limb development, and facial dysmorphism.

### A Family of EEC-like Syndromes

A group of multiple-congenital-anomaly syndromes is characterized by EEC. The prototypic EEC syndrome has this triad of features (Rudiger et al. 1970). EEC syndrome frequently presents with other associated anomalies, such as lacrimal-tract anomalies, urogenital anomalies, anal atresia, and conductive hearing loss (Rudiger et al. 1970; Rodini and Richieri-Costa 1990; Roelfsema and Cobben 1996). EEC syndrome is relatively common, with >200 cases having been reported in the literature, and is well known for having both variable expressivity and reduced penetrance. A comparison of interfamilial and intrafamilial variability in expressivity found significantly greater interfamilial variability, suggesting that more than one gene or allele might be involved (Roelfsema and Cobben 1996). Several autosomal dominant syndromes have been described that share features with EEC (table 1), including lacrimo-auricular-dental-digital (LADD) syndrome (MIM 149730) and LMS. Bamshad et al. (2000) proposed the combination of the aforementioned four syndromes as “LEAD syndrome” (named for limb, lacrimal, ectodermal, and apocrine dysplasia). Other dominant syndromes resemble the EEC syndrome in only one or two of the cardinal features; for example, AEC syndrome (also known as “Hay-Wells syndrome”) and Rapp-Hodgkin syndrome (RHS [MIM 129400]) lack ectrodactyly, the ectrodactyly–cleft palate (ECP) syndrome (MIM 129830) lacks ectodermal dysplasia, ADULT syndrome and the ectrodactyly–ectodermal dysplasia (EE) syndrome (MIM 129810) lack cleft lip with or without cleft palate (CL/P), and isolated SHFM is characterized only by ectrodactyly.

### *TP63* Mutations: All in the Family

In 1999, linkage mapping of human EEC-like syndromes identified a locus on 3q27, coinciding with the localization of *TP63*. This result, combined with the data generated by the basic biological research on p63, suggested that *TP63* was a strong positional candidate gene, which led to the rapid identification of causative *TP63* gene mutations in patients with EEC syndrome (Celli et al. 1999). At the same time, these results established that

**Table 1****Phenotypic Characteristics of Human Syndromes**

	HUMAN SYNDROME								
	EEC Syndrome	EE Syndrome	AEC Syndrome	RHS	LMS	SHFM	ADULT Syndrome	LADD Syndrome	ECP Syndrome
<b>Limb:</b>									
Split hand/split foot	++	+++	-	-	++	+++	++	-	+++
Fused digits, other	++	-	+/-	-	++	++	++	++	+
<b>Ectodermal:</b>									
Hair	+	++	+++	+++	-	-	+	-	-
Skin	+	-	+++	+	-	-	++	-	-
Nail	+	-	++	++	+/-	-	+	-	-
Teeth	+	++	++	++	+/-	-	++	++	-
Lacrimal ducts	+	-	+	++	+	-	+	++	-
Sweat glands	+	-	++	++	+	-	-	-	-
Breast/nipple hypoplasia	+/-	-	-	-	+++	-	+	-	-
<b>Facial:</b>									
CL/P	+++	-	+	+	-	-	-	-	-
CP	-	-	+	++	+	-	-	-	+++
Microretrognathia	+	-	+	-	-	-	-	++	-
<b>Other:</b>									
Fused eyelid	-	-	+++	-	-	-	-	-	-
Supernumerary nipple	+/-	-	+	-	-	-	-	-	-
Poor saliva production	-	-	-	-	-	-	-	++	-
Deformed ears/ear canals	+	-	-	+	-	-	-	+++	-
Hearing loss	+	-	+	-	-	-	-	+	-
Extensive freckling	-	-	-	-	-	-	+++	-	-
Kidney hypoplasia	+	-	+	-	-	-	-	+	-
Urethra/bladder	+	-	-	-	-	-	-	-	-
Hypospadias	-	-	-	+	-	-	-	+	-

NOTE.—+++ = Consistent feature; ++ = frequently observed; + = occasionally observed; +/- = rarely observed; - = never observed.

germline mutations in p63 are not associated with a cancer-prone phenotype, as is the case for p53/Li-Fraumeni syndrome. Moreover, the implication of p63 in EEC syndrome paved the way to testing of the *TP63* gene in the EEC-like syndromes, and by that, provided insight into the molecular mechanisms underlying this group of disorders (table 2).

### EEC Syndrome

To date, 20 different heterozygous p63 mutations in 53 families with EEC syndrome are known (reported by Celi et al. [1999], Ianakiev et al. [2000], Wessagowit et al. [2000], Kosaki et al. [2001], and van Bokhoven et al. [2001], as well as in the present article). Of the 50 families for which the entire *TP63*-coding region was tested in our laboratory, mutations were found in 49, indicating that the p63 gene accounts for many, if not all, patients with this syndrome. The patients with EEC syndrome who had chromosomal abnormalities on 7q21-q22, overlapping the *SHFM1* locus (MIM 183600), may be rare exceptions; note that such patients rarely have the full EEC syndrome phenotype (Scherer et al. 1994). Also note that many patients and small families with p63 mutations have all of the clinical hallmarks of EEC syndrome except for CL/P,

suggesting that EE syndrome (Wallis 1988) is a variable expression of the EEC syndrome. Two mutations, Y192C and V202M, were observed only in patients with an EE syndrome phenotype. All except one of the mutations in families with EEC syndrome give rise to amino acid substitutions in the DBD that is common to all known p63 isoforms. The arginine codons 204, 227, 279, 280, and 304 were mutated in several unrelated patients. These amino acids are crucially important for direct interactions with DNA target sequences, and their mutation is highly detrimental to DNA binding and transactivation activity.

Strikingly, most of the p63 germline mutations correspond precisely to the somatic mutational hotspots in the p53 gene in tumors (fig. 2). An exception is R227 in p63 (corresponding to R196 in p53, which is infrequently mutated in tumors), and the lack of mutations at amino acids G276 and R313, which correspond to the p53 mutational hotspots G245 and R282, respectively (fig. 2). Two explanations, which are not mutually exclusive, may account for the highly specific distribution of p63 mutations.

One explanation is the high mutability of the corresponding codons. Indeed, 46 of the 51 mutations in families with EEC syndrome are C→T transitions at CpG sites. Hence, the high mutability of 5-methylcy-

**Table 2****TP63 Mutations in EEC Syndrome, LMS, AEC Syndrome, ADULT Syndrome, and Isolated SHFM**

Amino Acid Change	No. of Families ( <i>n</i> = 78)	CpG Islet <sup>a</sup>	Disorder(s)	Reference(s)
Exon 3: N6H	1	–	ADULT syndrome	Amiel et al. 2001
Exon 4: G76W	1	–	LMS	Authors' unpublished data
Exon 5: IVS4-2A→C <sup>b</sup>	1	–	SHFM	van Bokhoven et al. 2001
Y163C	1	–	EEC syndrome	Authors' unpublished data
Y192C	2	–	EE syndrome	Authors' unpublished data
K193E	1	–	SHFM	van Bokhoven et al. 2001
K194E	1	–	SHFM	Ianakev et al. 2000
V202M	1	–	EE syndrome	Authors' unpublished data
Exon 6: R204W	6	+	EEC syndrome	Celli et al. 1999, van Bokhoven et al. 2001
R204Q	4	+	EEC syndrome	van Bokhoven et al. 2001, authors' unpublished data
R227Q	4	+	EEC syndrome	Authors' unpublished data
Exon 7: C269Y	1	–	EEC syndrome	van Bokhoven et al. 2001
S272N	1	–	EEC syndrome	Celli et al. 1999
C273Y	1	–	EEC syndrome	Authors' unpublished data
R279H	8	+	EEC syndrome	Celli et al. 1999, Ianakev et al. 2000, van Bokhoven et al. 2001, authors' unpublished data
R279C	3	+	EEC syndrome	Kosaki et al. 2001, van Bokhoven et al. 2001
R279Q	1	–	EEC syndrome	van Bokhoven et al. 2001
R280C	5	+	EEC syndrome, SHFM	Ianakev et al. 2000, van Bokhoven et al. 2001, authors' unpublished data
R280S	1	+	EEC syndrome	van Bokhoven et al. 2001
R280H	2	+	EEC syndrome, SHFM	van Bokhoven et al. 2001
R298Q	2	+	ADULT syndrome	Duijf et al. 2002, authors' unpublished data
Exon 8: R304W	4	+	EEC syndrome	Celli et al. 1999, Wessagowit et al. 2000, van Bokhoven et al. 2001, authors' unpublished data
R304Q	6	+	EEC syndrome	Ianakev et al. 2000, van Bokhoven et al. 2001
C306R	1	–	EEC syndrome	Celli et al. 1999
C308S	1	–	EEC syndrome	van Bokhoven et al. 2001
P309S	1	–	EEC syndrome	van Bokhoven et al. 2001
D312H	1	–	EEC syndrome	van Bokhoven et al. 2001
Exon 11: IVS10-2A→G <sup>b</sup>	1	–	AEC syndrome	Barrow et al., in press
Exon 13: L518V	1	–	AEC syndrome	McGrath et al. 2001
L518F	1	–	AEC syndrome	McGrath et al. 2001
C526G	1	–	AEC syndrome	McGrath et al. 2001
C526W	1	–	AEC syndrome	McGrath et al. 2001
1689InsA	1	–	EEC syndrome	Celli et al. 1999
1693-1694DelTT	1	–	LMS	van Bokhoven et al. 2001
G534V	1	–	AEC syndrome	McGrath et al. 2001
T537P	1	–	AEC syndrome	McGrath et al. 2001
Q540L	1	–	AEC syndrome	McGrath et al. 2001
I541T	2	–	AEC syndrome	McGrath et al. 2001, authors' unpublished data
Exon 14: 1859DelC	1	–	AEC syndrome	Authors' unpublished data
1860-1861DelAA	1	–	LMS	van Bokhoven et al. 2001
Q634X	1	–	SHFM	van Bokhoven et al. 2001
E639X	1	–	SHFM	Authors' unpublished data


<sup>a</sup> + = Mutation at a CpG site (*n* = 45); – = mutation not at a CpG site (*n* = 33).

<sup>b</sup> Intron mutation detected on analysis of the indicated exons.

tosine at CpG sites is a likely explanation for the high proportion of recurrent mutations in EEC syndrome. This would fit with the notion that the codons of the p53 mutational hotspots G245 and R282 contain a

CpG, whereas the codons for the nonmutated p63 counterparts G276 and R313 do not have a CpG site.

Another explanation, however, is that these recurrent mutations reflect a specific pathogenetic mechanism. This



**Figure 2** Distribution of missense mutations in the DBDs of p53 and p63. Amino acid–sequence comparison of the DBDs of p53, p63, and p73 reveals a high conservation, especially in the core domains (*boxed*). Within these core domains, amino acids that directly interact with the DNA and amino acids that form the Zn-binding pocket of the protein are highlighted. The black bars on top represent the incidence of somatic p53 mutations in tumors at the corresponding amino acids; the colored bars beneath the sequences represent the incidence of p63 mutations in the indicated human disorders. The p53-mutation spectrum is based on the IARC TP53 Mutation Database.

possibility is supported by the finding that a number of different missense mutations occurred at amino acids R204W/Q, R279C/H/Q, R280C/H/S, and R304W/Q, all of which give rise to EEC syndrome. In contrast, mutations elsewhere in the p63 protein yield phenotypically distinguishable syndromes.

These two explanations are not mutually exclusive, since disease-causing mutations may also be those of DNA sites that are readily mutable. Regardless, it is now clear that mutations in domains other than the DBD give rise to related but clinically distinguishable syndromes, suggesting that there is a specific relationship between *TP63* alleles and disease.

Analysis of the primary amino acid sequence (fig. 2)

and modeling of the structure of the p63 DBD predicted, for the mutant p63 proteins in EEC syndrome, a general disruptive effect on the DNA-binding capacity (Celli et al. 1999). Support for this prediction was provided by functional studies with mutant proteins in EEC syndrome. Mutant TA-p63 $\gamma$  isotypes were no longer able to promote the expression of a reporter gene, in contrast to their wild-type counterpart. Also, mutant  $\Delta$ N-p63 $\alpha$  was unable to compete with p53 for binding to this target site. These data established that missense mutations in EEC syndrome disrupt DNA binding for all p63 isotypes. The effects on transactivation will differ, however, depending on the sum of the transactivating TA-p63 $\gamma$  and the dominant-negative  $\Delta$ N-p63 $\alpha$  activities,

thereby making it difficult to predict the net result on transactivation *in vivo*. A single frameshift mutation found in a patient with EEC syndrome did not disrupt the DNA-binding capacity. Strikingly, this frameshift mutation, which affects the p63 $\alpha$  isotypes only, conferred a gain of transactivation on the otherwise repressive  $\Delta$ N-p63 $\alpha$  isotype (Celli et al. 1999).

### AEC (Hay-Wells) Syndrome

AEC syndrome, which is also known as “Hay-Wells syndrome,” has little or no limb involvement but instead includes ankyloblepharon, which is a partial or complete fusion of the eyelids that is very rare in other EEC-like syndromes (Hay and Wells 1976). Also, the ectodermal dysplasia is much more pronounced in AEC than in the other EEC-like syndromes. Severe infections of the scalp are common during the first years of life. Mutations in 12 unrelated patients with AEC have been detected, and 10 of these mutations are missense mutations within the SAM domain of p63 (McGrath et al. 2001). These mutations are predicted to disrupt protein-protein interactions, by either destroying the compact globular structure of the SAM domain or substituting amino acids that are crucial for such interactions (McGrath et al. 2001). Further interpretation of the consequences of the SAM-domain mutations is obscured by our ignorance of the normal biological role of this domain. The missense mutations in AEC syndrome affect only the  $\alpha$  isotypes of p63, which behave as inhibitors of transactivation. Transactivation studies did not reveal any increase in activity for mutant TA-p63 $\gamma$ , indicating that the SAM-domain mutations do not relieve the intramolecular repressive activity. In contrast, cotransfections of mutant  $\Delta$ N-p63 $\alpha$  with wild-type p53 or TA-p63 $\gamma$  revealed a clear decrease of intermolecular repressive activity. Tentative evidence indicates that the effects of the SAM-domain mutations varies for different isotypes and at different DNA target sites (L. Guerrini, personal communication). For the functional and developmental consequences of these mutations to be better understood, it will be necessary to identify the protein(s) interacting with the SAM domain.

### ADULT Syndrome

ADULT syndrome differs from EEC syndrome by the absence of facial clefting in patients with the former (Propping and Zerres 1993). Instead, these patients show neurodermitic signs—namely, exfoliative dermatitis of the digits—and excessive freckling. Linkage studies in one large German family indicated allelism with EEC syndrome, and, indeed, a pathogenetic mutation, R298Q, was found in the p63 gene (Propping et al. 2000; Duijf et al. 2002). The same R298Q mutation

was recently found in an unrelated Italian family with ADULT syndrome. Another missense mutation was reported in an isolated patient with features of ADULT syndrome (Amiel et al. 2001). This mutation lies in exon 3' and results in a substitution (N6H) that is specific to the  $\Delta$ N-p63 isotypes.

### LMS

LMS differs from EEC syndrome in at least three respects. First, mammary-gland and nipple hypoplasia are consistent features of LMS but are only occasionally seen in EEC syndrome. Second, patients with LMS do not have the hair and skin defects that are seen in EEC syndrome. Third, whereas patients with LMS have CP (van Bokhoven et al. 1999), those with EEC syndrome have CL/P but never have CP only. Phenotypically, LMS is most similar to ADULT syndrome (Propping et al. 2000). Three different mutations have been detected in patients with LMS. Two isolated patients with an LMS phenotype have, in exons 13 and 14, frameshift mutations that result in truncations of the p63 $\alpha$  protein. Therefore, the abundant p63 product in epithelial cells would be missing the TID. The third mutation was identified in the large Dutch family with LMS (van Bokhoven et al. 1999). The mutation is in exon 4 and creates a substitution (G76W) just upstream from the TA domain (P. Duijf, personal communication).

### SHFM

SHFM is genetically heterogeneous, and three loci have previously been identified by linkage analysis and study of *SHFM1*, on 7q21-q22; *SHFM2* (MIM 313350), on Xq26; and *SHFM3* (MIM 600095), on 10q24. In two affected families, SHFM chromosomal abnormalities did not map to any of these established loci but instead mapped to 3q27-q28, thereby indicating the existence of a fourth locus (*SHFM4* [MIM 605289]) (Ianakiev et al. 2000). Causative *TP63* mutations were found in both families. A subsequent analysis of a group of ~50 unrelated patients with SHFM revealed five mutations, suggesting that p63 mutations account for ~10% of these cases (van Bokhoven et al. 2001). Five of the seven p63 mutations seen in patients with SHFM are unique to this syndrome—namely, missense mutations K193E and K194E, nonsense mutations Q634X and E639X, and splice-site mutation IVS4-2A→C (which causes the insertion of a proline residue at position 233). The two aforementioned nonsense mutations create truncations of eight and three amino acids, respectively, in the C-terminal end of the  $\alpha$  isotypes. This C-terminal domain contains the repressive domain, and removal of the last eight amino acids partially abolishes this repression (V. Doetsch, personal communication). In addition, the last



five amino acids, KEEGE, may form an endoplasmic retention signal, suggesting that protein routing may also be impaired. Two other mutations, both at the same codon, have been found in both SHFM and EEC syndrome—namely, R280C and R280H. This arginine, like the lysines at positions 193 and 194, is not in direct contact with the DNA, and mutation of these residues probably induces more-subtle effects on the DNA-binding capacity of p63.

### Involvement of p63 in Other EEC-like Syndromes

We and others have tested a number of patients with LADD syndrome (Hollister et al. 1973; Amiel et al. 2001; authors' unpublished data). A nucleotide change that creates a P472T substitution was identified in an isolated patient with LADD syndrome. Although this change was not detected in >250 individuals (185 healthy controls and 78 patients with an EEC-like syndrome), it is likely to reflect a polymorphism, since the healthy father was also carrying the same change. Hence, it appears that p63 mutations do not account for LADD syndrome. The anticipated involvement in other related conditions, such as ECP syndrome and RHS (Rapp and Hodgkin 1968; Opitz et al. 1980), still needs to be established.

### Genotype-Phenotype Correlations: Molecular Dissection of the p63 Gene

The pattern of mutations in the five human disorders linked to p63 reveals a remarkable specificity of the molecular defects in this gene and clinical consequences. The clustering of mutations—in the DBD, for EEC syndrome, and in the SAM domain, for AEC syndrome—establishes a clear genotype-phenotype correlation. Furthermore, the mutations in ADULT syndrome, as well as most of the mutations in LMS and SHFM, are distinctive to these syndromes.


A number of observations can be made from more-detailed analysis of the pattern of *TP63* mutations (fig. 3). First, it is notable that the truncating mutations are all located in the C-terminal part of the protein. Hence, all p63 mutations known to date leave the ISO domain intact. This allows the formation of tetrameric complexes between wild-type and mutant p63 proteins, which offers an explanation for the dominant effect of p63 mutations. We have previously rejected haploinsufficiency as an explanation for the disease mechanism, because patients with a heterozygous deletion on 3q27-q29, encompassing the p63 gene, do not display signs of EEC syndrome (Chitayat et al. 1996; van Bokhoven et al. 2001).

The genotype-phenotype comparison suggests that there are further associations with regard to the occurrence of ectrodactyly and the type of facial clefting. Ectrodactyly is only seen in combination with missense

mutations before or in the DBD of p63 or in combination with truncating mutations in the C-terminal part of the protein. In contrast, missense mutations in the C-terminal part are never associated with ectrodactyly. A second remarkable phenomenon involves the type of facial clefting. The facial clefts seen in conjunction with missense mutations in the conserved part of the DBD always involve the primary palate (CL/P), whereas mutations toward the C-terminal end of p63 may either involve the primary palate or the secondary palate (CP). Also, the most N-terminal amino acid substitutions, which are located outside the conserved regions of the DBD, give rise to either CP or no clefting at all but never CL/P. The distinction between CL/P and CP is relevant, from both genetic and developmental points of view (Fraser 1970; Ferguson 1988). Anatomically, the primary palate and the secondary palate form independently of one another. Genetically, CL/P and CP also appear to be distinct, since the mixture of these types of facial clefting is rarely observed within families. The Van der Woude and AEC syndromes are rare examples of mixture of embryological and genetic types of facial clefting (CL/P vs. CP) (Schinzel and Klausler 1986). The pattern of mutations associated with ectrodactyly and with the type of facial clefting provides a basis for our conceptual thinking about the normal and abnormal activities, in developmental cascades, of p63.

The genotype-phenotype correlations are extended by the mutations found in ADULT syndrome. Like most mutations in EEC syndrome, the R298Q mutation in ADULT syndrome causes an amino acid substitution in the DBD (Duijf et al. 2002). Yet, this mutation is strikingly different from the mutations in EEC syndrome, since, on the basis of the structural model of the DBD, the arginine at position 298 itself does not participate in DNA binding. This prediction was supported by transactivation assays, which revealed no significant loss of activity for TA-p63<sup>R298Q</sup>, in sharp contrast to EEC-associated mutations of the same p63 isotype (Duijf et al. 2002). Although this result was predicted, an unexpected finding was the exceptional high transactivation activity for mutant  $\Delta$ N-p63<sup>R298Q</sup>, because this isoform is usually inert in these assays, since it lacks the canonical TA domain. We offer two explanations for this gain of transactivation activity: (1) The mutation creates a novel site for binding of a transcriptional coactivator. (2) The mutation releases a second TA domain (denoted as "TA2") that is normally kept in an inactive state. Although the first option is already less likely from a mechanistic point of view, there is additional support for the second possibility from studies in cell lines with inducible p63 expression (Dohn et al. 2001). In the present study, we provide evidence that there is, in the N-terminal end of p63, a TA2 domain, encompassing 14 amino acids from the  $\Delta$ N-specific end and 12 amino





**Figure 4** A gain-of-function mutation in ADULT syndrome reveals a second TA domain (TA2) in p63. **A** and **B**, Models explaining the gain-of-function effect that the R298Q mutation has on the  $\Delta N$ -p63 $\gamma$  isotype, which normally does not possess transactivation. The TA2 domain is normally kept in an inactive state, either because of intramolecular interaction (**A**) or because of binding of another protein (**B**). This inhibition is proposed to be released in patients with ADULT syndrome because the R298Q mutation abolishes this protein-protein interaction. DNA-BD = DBD; Iso = ISO domain; TA2 = TA2 domain. **C**, Position of TA2 domain, as determined by Dohn et al. (2001). The TA2 domain consists of 14 amino acids specific to the  $\Delta N$  isotypes and 12 amino acids common to all p63 isotypes. Interestingly, another ADULT-syndrome mutation and an LMS mutation both give rise to amino acid substitutions within the TA2 domain. DNA binding = DBD; Iso = ISO domain.

but one is seen in LMS, whereas the other is seen in AEC syndrome. The variable outcome of these mutations suggests the influence of additional genetic or environmental factors. Interestingly, within families, mutation of the arginine at position 280 always has the same phenotypic outcome—namely, either SHFM or EEC syndrome—supporting the notion that genetic modifiers or epigenetic factors have a modulatory effect.

Evidence for genetic modifiers is found in mice with mutations in genes that are likely to be involved in p63 pathways. The limb phenotype of the *dactylaplasia* (*Dac*) mouse, a model for human *SHFM3*, not only requires mutation of the *dactylin* gene but also requires homozygosity for an as-yet-unknown modifier allele that has been denoted as “*mDac*” (Sidow et al. 1999). Another fascinating example, in the *syndactylism* (*sm*) mouse, is caused by a disruption of the p63 target gene *Jag2* (Sidow et al. 1997; Sasaki et al. 2002). The *sm* phenotype is strongly modified by genetic background,

and several loci, acting as either enhancers or suppressors, have been mapped (Sidow et al. 1997). One of these, the suppressor locus on mouse chromosome 16, is syntenic to human chromosome 3q27-q29 and encompasses the *TP63* gene. *TP63* may be a modifier of the mutant *JAG2* phenotype, and, by analogy, *JAG2* may be a modifier of the mutant p63 phenotype. The hypothesis that there are specific modifier genes can be further pursued by molecular studies of large families with a single *TP63* mutation. Other candidate modifiers include (a) genes that are known to be mutated in human syndromes with features that overlap those of the EEC syndrome or (b) genes that are active in genetic programs that are governed by p63. For full comprehension of the normal and disrupted properties of the complex array of p63 isotypes, it will be necessary to identify those genes that act together with or in response to p63. It is to be expected that some of these will be found either to be modifiers of the spectrum of EEC-like disorders or to underlie LADD syndrome or the 90% of cases of SHFM that lack *TP63* mutations.

## Acknowledgments

We are indebted to the members of the Nijmegen Human Genetics laboratory—in particular, Pascal Duijf, Jacopo Celli, and Ellen van Beusekom. The continuous support from and discussions with our collaborators Frank McKeon, Annie Yang, Volker Doetsch, and John McGrath is greatly appreciated. Special thanks to Ben Hamel and Arie Smits for their studies of the family with LMS. Finally, we would like to thank Hans Scheffer, the many clinicians from other Institutes, and, most of all, the patients, for their participation in the studies described. Work in our laboratory is supported by grants from the Dutch Foundation for Scientific Research (NWO 903-42-190).

## Electronic-Database Information

Accession numbers and URLs for data presented herein are as follows:

IARC TP53 Mutation Database, <http://www.iarc.fr/p53/> (for mutation frequencies in the *TP53* gene)  
 Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim/> (for EEC syndrome [MIM 604292], LADD syndrome [MIM 149730], ADULT syndrome [MIM 103285], LMS [MIM 603543], AEC syndrome [MIM 106260], RHS [MIM 129400], ECP syndrome [MIM 129830], EE syndrome [MIM 129810], *SHFM1* [MIM 183600], *SHFM2* [MIM 313350], *SHFM3* [MIM 600095], and *SHFM4* [MIM 605289])

## References

Amiel J, Bougeard G, Francannet C, Raclin V, Munnich A, Lyonnet S, Frebourg T (2001) *TP63* gene mutation in ADULT syndrome. *Eur J Hum Genet* 9:642–645  
 Bakkers J, Hild M, Kramer C, Furutani-Seiki M, Hammer-

- schmidt M (2002) Zebrafish  $\Delta Np63$  is a direct target of Bmp signaling and encodes a transcriptional repressor blocking neural specification in the ventral ectoderm. *Dev Cell* 6:617–627
- Bamberger C, Pollet D, Schmale H (2002) Retinoic acid inhibits downregulation of  $\Delta Np63\alpha$  expression during terminal differentiation of human primary keratinocytes. *J Invest Dermatol* 118:133–138
- Bamberger C, Schmale H (2001) Identification and tissue distribution of novel KET/p63 splice variants. *FEBS Lett* 501:121–126
- Bamshad M, Jorde LB, Carey JC (2000) Getting a LEAD on EEC. *Am J Med Genet* 90:183–184
- Barrow LL, van Bokhoven H, Daack-Hirsch S, Andersen T, van Beersum SEC, Gorlin R, Murray JC. Analysis of the p63 gene in classic EEC syndrome, related syndromes, and nonsyndromic orofacial clefts. *Am J Med Genet* (in press)
- Bork P, Koonin EV (1998) Predicting functions from protein sequences—where are the bottlenecks? *Nat Genet* 18:313–318
- Calabro V, Mansueto G, Parisi T, Vivo M, Calogero RA, La Mantia G (2002) The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. *J Biol Chem* 277:2674–2681
- Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP, Newbury-Ecob R, Hennekam RC, Van Buggenhout G, van Haeringen A, Woods CG, van Essen AJ, de Waal R, Vriend G, Haber DA, Yang A, McKeon F, Brunner HG, van Bokhoven H (1999) Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. *Cell* 99:143–153
- Chi SW, Ayed A, Arrowsmith CH (1999) Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain. *EMBO J* 18:4438–4445
- Chitayat D, Babul R, Silver MM, Jay V, Teshima IE, Babyn P, Becker LE (1996) Terminal deletion of the long arm of chromosome 3 [46,XX,del(3)(q27→qter)]. *Am J Med Genet* 61:45–48
- De Laurenzi V, Rossi A, Terrinoni A, Barcaroli D, Levrero M, Costanzo A, Knight RA, Guerrieri P, Melino G (2000) p63 and p73 transactivate differentiation gene promoters in human keratinocytes. *Biochem Biophys Res Commun* 273:342–346
- Dohn M, Zhang S, Chen X (2001) p63 $\alpha$  and  $\Delta Np63\alpha$  can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. *Oncogene* 20:3193–3205
- Duijf PHG, Vanmolkot KRJ, Propping P, Friedl W, Krieger E, McKeon F, Dötsch V, Brunner HG, van Bokhoven H (2002) Gain-of-function mutation in ADULT syndrome reveals the presence of a second transactivation domain in p63. *Hum Mol Genet* 11:799–804
- Ferguson MW (1988) Palate development. *Development Suppl* 103:41–60
- Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T (2002) p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. *Nature* 416:560–564
- Fraser FC (1970) The genetics of cleft lip and cleft palate. *Am J Hum Genet* 22:336–352
- Hagiwara K, McMenamin MG, Miura K, Harris CC (1999) Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. *Cancer Res* 59:4165–4169
- Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. *Nature* 387:296–299
- Hay RJ, Wells RS (1976) The syndrome of ankyloblepharon, ectodermal defects and cleft lip and palate: an autosomal dominant condition. *Br J Dermatol* 94:277–289
- Hollister DW, Klein SH, De Jager HJ, Lachman RS, Rimoin DL (1973) The lacrimo-auriculo-dento-digital syndrome. *J Pediatr* 83:438–444
- Ianakiiev P, Kilpatrick MW, Toudjarska I, Basel D, Beighton P, Tsipouras P (2000) Split-hand/split-foot malformation is caused by mutations in the p63 gene on 3q27. *Am J Hum Genet* 67:59–66
- Jiang R, Lan Y, Chapman HD, Shawber C, Norton CR, Serreze DV, Weinmaster G, Gridley T (1998) Defects in limb, craniofacial, and thymic development in Jagged2 mutant mice. *Genes Dev* 12:1046–1057
- Jost CA, Marin MC, Kaelin WG Jr (1997) p73 is a human p53-related protein that can induce apoptosis. *Nature* 389:191–194 (erratum 399:817 [1999])
- Kadokia M, Slader C, Berberich SJ (2001) Regulation of p63 function by Mdm2 and MdmX. *DNA Cell Biol* 20:321–330
- Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalou P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. *Cell* 90:809–819
- Kosaki R, Ohashi H, Yoshihashi H, Suzuki T, Kosaki K (2001) A *de novo* mutation (R279C) in the P63 gene in a patient with EEC syndrome. *Clin Genet* 60:314–315
- Kubbutat M, Jones S, Vousden K (1997) Regulation of p53 stability by Mdm2. *Nature* 387:299–303
- Levine AJ (1997) p53, the cellular gatekeeper for growth and division. *Cell* 88:323–331
- Liefer KM, Koster MI, Wang XJ, Yang A, McKeon F, Roop DR (2000) Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. *Cancer Res* 60:4016–4020
- Little NA, Jochemsen AG (2001) Hdmx and Mdm2 can repress transcription activation by p53 but not by p63. *Oncogene* 20:4576–4580
- McGrath JA, Duijf PH, Doetsch V, Irvine AD, de Waal R, Vanmolkot KR, Wessagowit V, Kelly A, Atherton DJ, Griffiths WA, Orlow SJ, van Haeringen A, Ausems MG, Yang A, McKeon F, Bamshad MA, Brunner HG, Hamel BC, van Bokhoven H (2001) Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. *Hum Mol Genet* 10:221–229
- Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. *Nature* 398:708–713
- Nishi H, Senoo M, Nishi KH, Murphy B, Rikiyama T, Matsumura Y, Habu S, Johnson AC (2001) p53 homologue p63 represses epidermal growth factor receptor expression. *J Biol Chem* 276:41717–41724
- Opitz JM, Frias JL, Cohen MM Jr (1980) The ECP syndrome, another autosomal dominant cause of monodactylous ectrodactyly. *Eur J Pediatr* 133:217–220
- Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M,

- Ikawa S (1998) Cloning and functional analysis of human p51, which structurally and functionally resembles p53. *Nat Med* 4:839–843
- Ozaki T, Naka M, Takada N, Tada M, Sakiyama S, Nakagawara A (1999) Deletion of the COOH-terminal region of p73 $\alpha$  enhances both its transactivation function and DNA-binding activity but inhibits induction of apoptosis in mammalian cells. *Cancer Res* 59:5902–5907
- Pochampally R, Li C, Lu W, Chen L, Luftig R, Lin J, Chen J (2000) Temperature-sensitive mutants of p53 homologs. *Biochem Biophys Res Commun* 279:1001–1010
- Propping P, Friedl W, Wienker TF, Uhlhaas S, Zerres K (2000) ADULT syndrome allelic to limb mammary syndrome (LMS)? *Am J Med Genet* 90:179–182
- Propping P, Zerres K (1993) ADULT-syndrome: an autosomal-dominant disorder with pigment anomalies, ectrodactyly, nail dysplasia, and hypodontia. *Am J Med Genet* 45:642–648
- Rapp RS, Hodgkin WE (1968) Anhidrotic ectodermal dysplasia: autosomal dominant inheritance with palate and lip anomalies. *J Med Genet* 5:269–272
- Rodini ES, Richieri-Costa A (1990) EEC syndrome: report on 20 new patients, clinical and genetic considerations. *Am J Med Genet* 37:42–53
- Roelfsema NM, Cobben JM (1996) The EEC syndrome: a literature study. *Clin Dysmorphol* 5:115–127
- Rudiger RA, Haase W, Passarge E (1970) Association of ectrodactyly, ectodermal dysplasia, and cleft lip-palate. *Am J Dis Child* 120:160–163
- Sasaki Y, Ishida S, Morimoto I, Yamashita T, Kojima T, Kihara C, Tanaka T, Imai K, Nakamura Y, Tokino T (2002) The p53 family member genes are involved in the Notch signal pathway. *J Biol Chem* 277:719–724
- Scherer SW, Poorkaj P, Massa H, Soder S, Allen T, Nunes M, Geshuri D, Wong E, Belloni E, Little S (1994) Physical mapping of the split hand/split foot locus on chromosome 7 and implication in syndromic ectrodactyly. *Hum Mol Genet* 3:1345–1354
- Schinzl A, Klausler M (1986) The Van der Woude syndrome (dominantly inherited lip pits and clefts). *J Med Genet* 23:291–294
- Schmale H, Bamberger C (1997) A novel protein with strong homology to the tumor suppressor p53. *Oncogene* 15:1363–1367
- Schultz J, Ponting CP, Hofmann K, Bork P (1997) SAM as a protein interaction domain involved in developmental regulation. *Protein Sci* 6:249–253
- Senoo M, Seki N, Ohira M, Sugano S, Watanabe M, Inuzuka S, Okamoto T, Tachibana M, Tanaka T, Shinkai Y, Kato H (1998) A second p53-related protein, p73L, with high homology to p73. *Biochem Biophys Res Commun* 248:603–607
- Shimada A, Kato S, Enjo K, Osada M, Ikawa Y, Kohno K, Obinata M, Kanamaru R, Ikawa S, Ishioka C (1999) The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. *Cancer Res* 59:2781–2786
- Sidow A, Bulotsky MS, Kerrebrock AW, Birren BW, Altshuler D, Jaenisch R, Johnson KR, Lander ES (1999) A novel member of the F-box/WD40 gene family, encoding dactylin, is disrupted in the mouse dactylaplasia mutant. *Nat Genet* 23:104–107
- Sidow A, Bulotsky MS, Kerrebrock AW, Bronson RT, Daly MJ, Reeve MP, Hawkins TL, Birren BW, Jaenisch R, Lander ES (1997) *Serrate2* is disrupted in the mouse limb-development mutant *syndactylism*. *Nature* 389:722–725
- Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, Oren M, Sudol M, Cesareni G, Blandino G (2001) Physical interaction with Yes-associated protein enhances p73 transcriptional activity. *J Biol Chem* 276:15164–15173
- Trink B, Okami K, Wu L, Sriuranpong V, Jen J, Sidransky D (1998) A new human p53 homologue. *Nat Med* 4:747–748
- van Bokhoven H, Hamel BC, Bamshad M, Sangiorgi E, Gurrieri F, Duijif PH, Vanmolkot KR, van Beusekom E, van Beersum SE, Celli J, Merckx GF, Tenconi R, Fryns JP, Verloes A, Newbury-Ecob RA, Raas-Rotschild A, Majewski F, Beemer FA, Janecke A, Chitayat D, Crisponi G, Kayserili H, Yates JR, Neri G, Brunner HG (2001) p63 gene mutations in EEC syndrome, limb-mammary syndrome, and isolated split hand-split foot malformation suggest a genotype-phenotype correlation. *Am J Hum Genet* 69:481–492
- van Bokhoven H, Jung M, Smits AP, van Beersum S, Schendorff R, van Steensel M, Veenstra M, Tuerlings JH, Mariman EC, Brunner HG, Wienker TF, Reis A, Ropers HH, Hamel BC (1999) Limb mammary syndrome: a new genetic disorder with mammary hypoplasia, ectrodactyly, and other hand/foot anomalies maps to human chromosome 3q27. *Am J Hum Genet* 64:538–546
- Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. *Nature* 408:307–310
- Wallis CE (1988) Ectrodactyly (split-hand/split-foot) and ectodermal dysplasia with normal lip and palate in a four-generation kindred. *Clin Genet* 34:252–257
- Wessagowit V, Mellerio JE, Pembroke AC, McGrath JA (2000) Heterozygous germline missense mutation in the p63 gene underlying EEC syndrome. *Clin Exp Dermatol* 25:441–443
- Yang A, Kaghad M, Caput D, McKeon F (2002) On the shoulders of giants: p63, p73 and the rise of p53. *Trends Genet* 18:90–95
- Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. *Mol Cell* 2:305–316
- Yang A, McKeon F (2002) P63 and P73: P53 mimics, menaces and more. *Nat Rev Mol Cell Biol* 1:199–207
- Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, McKeon F (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. *Nature* 398:714–718
- Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D (2000) p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. *Nature* 404:99–103
- Zhu J, Jiang J, Zhou W, Zhu K, Chen X (1999) Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity. *Oncogene* 18:2149–2155